metaPreg - Flunitrazepam during pregnancy

Flunitrazepam updated on 02-10-2025

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	1.33 [1.05, 1.69]	0%	2 studies	206,471	1,008	not evaluable	ROB	2.00 [1.28; .]
Congenital heart defects	1.64 [1.20, 2.24]	0%	2 studies	83,627	1,008	not evaluable	ROB	2.66 [1.70; .]
Major congenital malformations	1.33 [1.05, 1.69]	0%	2 studies	206,471	1,008	not evaluable	ROB	2.00 [1.28; .]
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preterm (< 37 weeks)	1.62 [1.44, 1.83]	-	1 study	275,110	2,581	not evaluable	ROB	2.62 [2.23; .]
Small for gestational age (weight)	1.60 [1.42, 1.81]	-	1 study	288,359	2,612	not evaluable	ROB	2.58 [2.18; .]
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
1 non statistically significant endpoints reported in only one study